Cyclacel Pharmaceuticals, Inc. CYCC is scheduled to release fourth-quarter 2019 results on Feb 26.

The companys surprise history has been impressive so far. The trailing four-quarter earnings beat is 16.56%, on average. In the third quarter, Cyclacel delivered a positive earnings surprise of 35.29%.

Shares of Cyclacel have lost 7.9% in the past year compared with theindustrysdecline of 2%.

Lets see how things are shaping up for the quarter to be reported.

Key Developments in Q4

Cyclacel is a biopharmaceutical company developing innovative medicines based on cancer cell biology. As the company does not have any marketed products in its portfolio, we expect it to provide updates on its pipeline during the fourth-quarter earnings call.

In December 2020, the company announced study design and preliminary data from two of the phase I studies, evaluating a combination of CYC065, a CDK2/9 inhibitor, and Venclexta(venetoclax), which is a BCL2 inhibitor, to treat patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) and chronic lymphocytic leukemia (CLL), respectively. We expect updates on this during the fourth-quarter earnings announcement.

The company is evaluating CYC140 in patients with advanced leukemias. CYC140 is a small molecule, selective polo-like-kinase 1 (PLK1) inhibitor that has demonstrated potent and selective target inhibition and high activity in xenograft models of human cancer. We expect the company to provide updates on the study during the fourth quarter earnings announcement.

The company isevaluating an oral regimen of sapacitabine in combination with venetoclax in patients with relapsed or refractory AML/MDS in a phase I/II study. We expect the company to provide an update on this study.

What Our Model Indicates

Our proven model does not conclusively predict an earnings beat for Cyclacel this season. The combination of a positiveEarnings ESPand a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here, as you will see below.

Earnings ESP:Cyclacel has an Earnings ESP of 0.00%, as both the Zacks Consensus Estimate and the Most Accurate Estimate are pegged at a loss of 12 cents. You can uncover the best stocks to buy or sell before theyre reported with ourEarnings ESP Filter.

Zacks Rank:The company carries a Zacks Rank #3. You can seethe complete list of todays Zacks #1 Rank stocks here.

Cyclacel Pharmaceuticals, Inc. Price and EPS Surprise

Cyclacel Pharmaceuticals, Inc. Price and EPS Surprise

Cyclacel Pharmaceuticals, Inc. price-eps-surprise | Cyclacel Pharmaceuticals, Inc. Quote

Stocks That Warrant a Look

Here are a few healthcare stocks worth considering, as our model shows that these have the right mix of elements to beat estimates this time around.

Vericel Corporation VCEL has an Earnings ESP of +11.29% and a Zacks Rank #1. The company is scheduled to release fourth-quarter results on Feb 25.

Story continues

Here is the original post:
Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards? - Yahoo Finance